cidrap.umn | Today during a meeting of the Advisory Committee on Immunization Practices (ACIP), a panel of expert advisors to the Centers for Disease Control and Prevention (CDC), discussed rare instances of heart inflammation among mRNA COVID-19 vaccine recipients. The committee agreed the vaccines are likely linked to cases of myocarditis and pericarditis but said the benefits of vaccination outweigh the risks.
The first reports of myocarditis and pericarditis occurred in Israel in January, the experts said, and have followed in all countries using mRNAs. The myocarditis (inflammation of heart muscle) and pericarditis (inflammation of the tissues surrounding the heart) associated with vaccines are usually mild and respond well to a course of treatment with non-steroidal anti-inflammatories.
"Clinical presentation of myocarditis cases following vaccination has been distinct, occurring most often within 1 week after dose two, with chest pain as the most common presentation, " said Grace Lee, MD, chair of ACIP's safety subcommittee.
"mRNA vaccines may be a new trigger for myocarditis, yet it does have some different characteristics," said Matthew Oster, MD, MPH, from the CDC's COVID-19 Vaccine Task Force.
The most common symptoms reported by patients were chest pain, shortness of breath, and difficulty sleeping.
Cases mostly in males under 30
Tom Shimabukuro, MD, MPH, MBA, the deputy director of the Immunization Safety Office at the CDC, said the agency has received reports of 1,226 cases of myocarditis, with 827 (67.5%) reported after dose two of either the Moderna or Pfizer vaccine.
Of those cases identified after second doses, 563 followed the Pfizer vaccine series. In total, that's approximately 12.6 heart inflammation cases per million doses administered in the United States.
Among the 1,226 patients, 484 are younger than 29, and roughly two-thirds are men.
0 comments:
Post a Comment